Investigate characteristics of over 17,000 unique ATN Profile patient results to understand how clinicians are employing blood-based biomarker panels with patients.
Though Alzheimer’s Disease (AD) accounts for most dementia cases, up to 40% of patients may have another type of dementia. Blood-based biomarkers (BBMs) for AD are now readily available, but how these markers are being employed in real-world clinical settings has not been extensively explored. To assist in guiding clinical investigation, four assays were combined to create the ATN Profile.
A review of unique patient results from ATN Profiles along with key demographic information was conducted. The ATN Profile consists of amyloid beta 42/40 ratio (Aβ42/40 = A), phosphorylated tau181 (pTau181 = T) and neurofilament light chain (NfL = N) measurements thereby offering eight possible result combinations.
A total of 17,498 ATN Profile unique patient results, mean (SD) age 73.6 (10.1) years and 56.5% female. The majority of patients were ages 55 or older (94.6%). All eight possible combinations of results were represented in the cohort and the percentage of patients with an A+ result was 53.9%. The percentage of patients who had all three biomarkers within normal range (A- T- N-) was 22.3%. Both the ATN Profile and APOE genotyping was performed on 24.9% of patients. Of those, 55.5% of A+ results had one or more copies of the APOE E4 allele. The percentage of patients who had an ICD10 code used was 92.1%. The top three ICD10 codes used included R41.3 (33.1%), G31.84 (20.5%), and F03.90 (9.5%), corresponding to “other amnesia”, “mild cognitive impairment”, and “unspecified dementia”, respectively.
Patient age and ICD10 code use imply that clinicians are employing these new AD BBMs in the correct patient cohorts. These results indicate that the ATN Profile can be an appropriate tool for triaging AD patients.